Cargando…

Aflibercept for treatment-naïve diabetic macula oedema in a multi-ethnic population: Real-world outcomes from North West London

PURPOSE: To evaluate the clinical outcomes of patients with treatment–naïve diabetic macula oedema (DMO) treated with Aflibercept in routine clinic settings in ethnically diverse North West London (NWL) and compare to outcomes reported in the VIVID and VISTA clinical trials METHODS: This was a retro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dinah, Christiana, Ghulakhszian, Arevik, Sim, Sing Yue, Minocha, Amal, Nokhostin, Soroush, Posner, Esther, Cheong-Lee, Richard, George, Sheena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877641/ https://www.ncbi.nlm.nih.gov/pubmed/33571295 http://dx.doi.org/10.1371/journal.pone.0246626

Ejemplares similares

Correction: Aflibercept for treatment-naïve diabetic macula oedema in a multi-ethnic population: Real-world outcomes from North West London
por: Dinah, Christiana, et al.
Publicado: (2021)

Factors Influencing Response to Aflibercept in Diabetic Macular Oedema Patients in a Diverse North West London Population: A Real-World Study
por: Sim, Sing Yue, et al.
Publicado: (2021)

Acceptability of intravitreal injections in geographic atrophy: protocol for a mixed-methods pilot study
por: Enoch, Jamie, et al.
Publicado: (2021)

Towards a Therapy for Geographic Atrophy: A Patient’s Experience
por: Enoch, Jamie, et al.
Publicado: (2023)

Piloting a forced-choice task to elicit treatment preferences in geographic atrophy
por: Enoch, Jamie, et al.
Publicado: (2023)

Exploring patient acceptability of emerging intravitreal therapies for geographic atrophy: A mixed-methods study
por: Enoch, Jamie, et al.
Publicado: (2023)

Comment on: Ranibizumab and aflibercept intravitreal injection for treatment naïve and refractory macular oedema in branch retinal vein occlusion
por: Elkazza, Sumeia A, et al.
Publicado: (2020)

Aflibercept versus ranibizumab for treating persistent diabetic macular oedema
por: ROA Vandekerckhove, Kristof
Publicado: (2015)

Aflibercept monotherapy versus aflibercept with targeted retinal laser to peripheral retinal ischemia for diabetic macular oedema (LADAMO)
por: Cornish, E. E., et al.
Publicado: (2023)

Intravitreal aflibercept for treatment of macular oedema associated with immune recovery uveitis
por: Rothova, Aniki, et al.
Publicado: (2020)

Evaluation of standard of care intravitreal aflibercept treatment of diabetic macular oedema treatment-naive patients in the UK: DRAKO study 12-month outcomes
por: Sivaprasad, Sobha, et al.
Publicado: (2021)

Combined Phacoemulsification and Intravitreal Dexamethasone Is an Effective Option for High-Risk Diabetic Macula Oedema Patients
por: Thirunavukarasu, Arun J, et al.
Publicado: (2021)

Macular Oedema in Idiopathic Macular Telangiectasia Type 1 Responsive to Aflibercept but Not Bevacizumab
por: Shibeeb, O'Sam, et al.
Publicado: (2014)

Aflibercept in Diabetic Macular Oedema Previously Refractory to Standard Intravitreal Therapy: An Irish Retrospective Study
por: McCloskey, Clare F., et al.
Publicado: (2018)

Retinal arteriolar oxygen saturation predicts the need for intravitreal aflibercept in patients with diabetic macular oedema
por: Blindbæk, Søren Leer, et al.
Publicado: (2020)

Two-year outcomes of the treat-and-extend regimen using aflibercept for treating diabetic macular oedema
por: Kim, Yu Cheol, et al.
Publicado: (2020)

Two Year Visual Acuity and Structural Outcomes in Patients with Diabetic Macular Oedema Treated with Intravitreal Aflibercept – A Retrospective Cohort Study
por: Kern, Christoph, et al.
Publicado: (2020)

Comparison of the intraocular pressure following an intravitreal triamcinolone acetonide injection for diabetic macula oedema in vitrectomised and non-vitrectomised eyes
por: Orii, Yusuke, et al.
Publicado: (2021)

Prospective exploratory study to assess the safety and efficacy of aflibercept in cystoid macular oedema associated with retinitis pigmentosa
por: Strong, Stacey A, et al.
Publicado: (2020)

Translating evidence into practice: recommendations by a UK expert panel on the use of aflibercept in diabetic macular oedema
por: Pearce, Ian, et al.
Publicado: (2019)

Predictors of mortality and ITU admission for COVID‐19 patients admitted to a London district general hospital: A retrospective cohort study
por: Alhilani, Michel, et al.
Publicado: (2021)

A Review of Aflibercept Treatment for Macular Disease
por: Anguita, Rodrigo, et al.
Publicado: (2021)

Survey of ophthalmology practitioners in A&E on current COVID-19 guidance at three Major UK Eye Hospitals
por: Minocha, Amal, et al.
Publicado: (2020)

Correction to: A Review of Aflibercept Treatment for Macular Disease
por: Anguita, Rodrigo, et al.
Publicado: (2021)

Cost-effectiveness of dexamethasone compared with aflibercept in naïve diabetic macular edema
por: Montes Rodríguez, Paula, et al.
Publicado: (2022)

Why the macula?
por: Bird, A. C., et al.
Publicado: (2017)

On Macula Cachectica
por: Whitehead, James
Publicado: (1859)

Efficacy and Safety of an Aflibercept Treat-and-Extend Regimen in Treatment-Naïve Patients with Macular Oedema Secondary to Central Retinal Vein Occlusion (CRVO): A Prospective 12-Month, Single-Arm, Multicentre Trial
por: Garcia-Arumi, Jose, et al.
Publicado: (2018)

Real-World Results of Switching Treatment from Ranibizumab to Aflibercept in Macular Oedema Secondary to Branch Retinal Vein Occlusion
por: Konidaris, Vasileios E., et al.
Publicado: (2018)

Evaluation of standard-of-care intravitreal aflibercept treatment practices in patients with diabetic macular oedema in the UK: DRAKO study outcomes
por: Sivaprasad, Sobha, et al.
Publicado: (2023)

Navigated laser and aflibercept versus aflibercept monotherapy in treatment‐naïve branch retinal vein occlusion: A 12‐month randomized trial
por: Frederiksen, Katrine Hartmund, et al.
Publicado: (2022)

The impact of compliance among patients with diabetic macular oedema treated with intravitreal aflibercept: a 48‐month follow‐up study
por: Angermann, Reinhard, et al.
Publicado: (2021)

12‐month outcomes of ranibizumab versus aflibercept for macular oedema in central retinal vein occlusion: data from the FRB! registry
por: Niedzwiecki, Mateusz, et al.
Publicado: (2021)

Pachychoroid Diseases of the Macula
por: Gallego-Pinazo, Roberto, et al.
Publicado: (2014)

Swiss-cheese macula
por: Shah, Kunal K, et al.
Publicado: (2020)

Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy
por: Singh, Sumit Randhir, et al.
Publicado: (2019)

Choroidal Thickness Changes After Intravitreal Aflibercept Injections in Treatment-Naïve Neovascular AMD
por: Minnella, Angelo Maria, et al.
Publicado: (2022)

Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study
por: Pennington, Becky, et al.
Publicado: (2021)

Evaluation of care with intravitreal aflibercept treatment for UK patients with diabetic macular oedema: DRAKO study 24-month real-world outcomes
por: Sivaprasad, Sobha, et al.
Publicado: (2023)

Intravitreal aflibercept partially reverses severe non-proliferative diabetic retinopathy in treatment-naïve patients
por: Tao, Yuan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_46evajtsg8toljirmh3c3k5ipo